Regulatory Action to Protect Access to Hydroxychloroquine for Approved Rheumatic Indications During COVID‐19 in New Zealand
| Autor: | Thomas Hills, Richard Beasley, Nicola Arroll, Eamon Duffy |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
viruses Immunology Off-label use medicine.disease_cause 030226 pharmacology & pharmacy Health Services Accessibility Dengue fever 03 medical and health sciences 0302 clinical medicine Rheumatology Chloroquine Rheumatic Diseases Pandemic medicine Humans Immunology and Allergy 030212 general & internal medicine Chikungunya Practice Patterns Physicians' Intensive care medicine Coronavirus Evidence-Based Medicine business.industry SARS-CoV-2 virus diseases Hydroxychloroquine Evidence-based medicine Off-Label Use medicine.disease United States COVID-19 Drug Treatment Antirheumatic Agents Drug and Narcotic Control business medicine.drug New Zealand |
| Zdroj: | Arthritis & Rheumatology |
| ISSN: | 2326-5205 2326-5191 |
| DOI: | 10.1002/art.41643 |
| Popis: | The rapid spread of coronavirus disease 2019 (COVID-19) brought into sharp focus the conundrum of how to balance evidence-based prescribing vs empiric treatment with repurposed drugs for a pandemic with a high mortality risk. Initial attention focused on hydroxychloroquine/chloroquine due to evidence of in vitro activity against the novel coronavirus SARS-CoV-2,1 yet the external validity of these data was limited by knowledge that in vitro antiviral activity did not equate to efficacy in randomised controlled trails (RCTs) of hydroxychloroquine/chloroquine treatment for influenza, dengue, chikungunya, and human immunodeficiency virus infection.1. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text